JAK1 and cancer: After trastuzumab treatment, both AKT and ERK phosphorylation were less downregulated while Jak1 and STAT3 phosphorylation were unregulated more obviously in EGFRvIII+HER2+ than in EGFRvIII−HER2+ cancer cell lines (Figure 1C and 1D).